The siRNA targeting Lp(a), zerlasiran, reduced time-averaged Lp(a) concentration by more than 80% during 26 weeks of treatment in patients with atherosclerotic cardiovascular disease (ASCVD), with reductions persisting for 60 weeks after the first dose. These were the key findings presented from the ALPACAR-360 trial, and published simultaneously in JAMA.
Educational Partners and Supporters
(Founding Partner)
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.